Novartis Vanrafia Phase III data support slowing of kidney function decline in patients with IgA nephropathy
Basel, February 13, 2026 – Novartis today announced final results from the…
Novartis breaks ground on new global Biomedical Research center in San Diego to accelerate drug discovery
Basel, February 6, 2026 – Novartis today broke ground on a new,…
Novartis ianalumab receives FDA Breakthrough Therapy designation for Sjgrens disease
Basel, January 16, 2026 – Novartis today announced that the US Food and…
Novartis to add radioligand therapy manufacturing facility in Winter Park, Florida, fourth in US to serve patients and advance $23 billion investment
Basel, January 9, 2026 – Novartis, a leading global innovative medicines company,…
Automobili Lamborghini brings Italian artistry to Miami Beach with a uniquely designed Temerario during Art Basel Miami 2025
The first Temerario delivered in the Americas highlights the extensive personalization possibilities…
Novartis data underscore pioneering scientific innovation in Hematology and Oncology at ASH and SABCS
Positive results from ianalumab pivotal Phase III trial in ITP patients previously…
Jungbunzlauer closes acquisition of Illinois facility to launch U.S. manufacturing operations
– Strategic investment enhances service to North American customers and supports rising…
Jungbunzlauer Tricalcium Citrate Excipient Demonstrates Outstanding Results in Direct Compression Study
- New research confirms Jungbunzlauer's TCC TB supports efficient, high-quality tablet manufacturing…
PSMAddition data show Novartis Pluvicto delays progression to end-stage prostate cancer
Basel, October 19, 2025 – Novartis today presents new Pluvictoâ„¢ (lutetium (177Lu)…
Roche presents new phase III pivotal data for vamikibart in uveitic macular edema (UME), a serious cause of vision loss
Vamikibart is the first non-steroid targeted therapy designed to address inflammation driving…